Anti Amyloid Kisunla denied as experimental or investigational by Humana?

Humana's specific coverage criteria for anti amyloid kisunla are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Kisunla as Experimental or Investigational

An "experimental or investigational" denial for Kisunla (donanemab) typically reflects a lag between the FDA's approval date and the update cycle of Humana's internal coverage policies, or a plan interpretation that the drug's clinical evidence base is insufficient for coverage despite FDA approval. This type of denial is particularly common in the early period after a novel drug class receives approval and before major payer policies are formally updated.

## Why This Denial Is Appealable

Kisunla received FDA approval for early symptomatic Alzheimer's disease. FDA approval is the regulatory standard for whether a drug is experimental — an approved drug is, by definition, not investigational for its approved indication when used in a patient who matches the approved population. Courts and external review organizations have consistently held that a plan cannot use an outdated or internally inconsistent policy to classify an FDA-approved drug as experimental. This category of denial has a strong track record of reversal at external review.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File immediately. Attach the FDA approval documentation. An experimental/investigational denial for an FDA-approved drug is a classification error, and it can often be corrected at the internal stage.
• External review: If the internal appeal is denied, independent external review under ACA §2719 is available. File within approximately four months of the final internal denial. External reviewers apply an objective standard of whether the drug is experimental — FDA approval is the threshold.
• Expedited review: Alzheimer's disease is a progressive condition. If delay causes clinical harm, request expedited processing.

## Documentation to Gather

1. FDA approval documentation — print the approval letter and prescribing label from Drugs@FDA. Highlight the indication, the approval date, and the patient population. This is the cornerstone of your appeal. 2. Humana's experimental/investigational criteria — obtain the specific policy text Humana cited in the denial. Identify whether its definition of "experimental" is consistent with FDA approval status. If the policy was last updated before the approval date, document that discrepancy. 3. Diagnosis and eligibility confirmation — neurologist or dementia specialist notes confirming early symptomatic Alzheimer's disease, amyloid confirmation (PET or CSF biomarker), and cognitive staging consistent with the FDA-approved indication per the prescribing label. 4. Prescriber medical-necessity letter — from the treating specialist confirming on-label use and the patient's match to the approved population, referencing applicable specialty society guidance (e.g., relevant Alzheimer's/dementia guideline organization) generically. 5. Coverage policy comparison — note whether Humana has updated its policy since the FDA approval date. If it has not, include the approval date as evidence the policy is stale.

## Criteria-Mapping Structure

Lead your appeal with a one-paragraph factual summary: FDA approved Kisunla on [approval date]; the patient's diagnosis and presentation match the approved indication; the drug is therefore not experimental for this use. Attach the FDA label as Exhibit A. Then address each element of Humana's denial letter directly. Experimental denials for approved drugs are among the most defensible at external review.